Sam Brusco04.02.24
Integra LifeSciences has completed its acquisition of Acclarent, a company specializing in ear, nose, and throat (ENT) surgical interventions.
The deal was first announced in December 2023.
Integra said adding Acclarent’s innovative portfolio will expand the breadth of its brands, as well as provide immediate scale and accretive growth. The acquisition, the company said, adds $1 billion to its total addressable market. It also provides market opportunities for access to the ENT device segment.
Integra already touts its MicroFrance line of ENT instruments and Acclarent’s portfolio adds groundbreaking balloon technologies for sinus and eustachian tube dilation as well as surgical navigation systems. Based in Irvine, Calif., Acclarent—formerly a Johnson & Johnson MedTech company—captures its revenues from U.S. sales, which reached $110 million in 2022. The company has R&D facilities in Irvine and Haifa, Israel. The company also utilizes third-party manufacturers.
Acclarent will become a part of Integra’s Codman Specialty Surgical division, which it also acquired from J&J MedTech in 2017.
“Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, enabling us to deliver transformative technologies to restore patients’ lives,” said Mike McBreen, executive VP and president, Codman Specialty Surgical division. “We are looking forward to working alongside our Acclarent colleagues to make a profound impact on ENT and neurosurgery care.”
The deal was first announced in December 2023.
Integra said adding Acclarent’s innovative portfolio will expand the breadth of its brands, as well as provide immediate scale and accretive growth. The acquisition, the company said, adds $1 billion to its total addressable market. It also provides market opportunities for access to the ENT device segment.
Integra already touts its MicroFrance line of ENT instruments and Acclarent’s portfolio adds groundbreaking balloon technologies for sinus and eustachian tube dilation as well as surgical navigation systems. Based in Irvine, Calif., Acclarent—formerly a Johnson & Johnson MedTech company—captures its revenues from U.S. sales, which reached $110 million in 2022. The company has R&D facilities in Irvine and Haifa, Israel. The company also utilizes third-party manufacturers.
Acclarent will become a part of Integra’s Codman Specialty Surgical division, which it also acquired from J&J MedTech in 2017.
“Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, enabling us to deliver transformative technologies to restore patients’ lives,” said Mike McBreen, executive VP and president, Codman Specialty Surgical division. “We are looking forward to working alongside our Acclarent colleagues to make a profound impact on ENT and neurosurgery care.”